Nurix Therapeutics upgraded by Morgan Stanley with a new price target
$NRIX
Biotechnology: Pharmaceutical Preparations
Health Care
Morgan Stanley upgraded Nurix Therapeutics from Equal-Weight to Overweight and set a new price target of $36.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2026 | $36.00 | Equal-Weight → Overweight | Morgan Stanley |
| 11/24/2025 | $30.00 | Buy | Truist |
| 10/21/2025 | $24.00 | Outperform | Mizuho |
| 3/17/2025 | $16.00 | Market Perform | Leerink Partners |
| 12/10/2024 | $35.00 | Buy | BTIG Research |
| 12/6/2024 | $35.00 | Outperform | BMO Capital Markets |
| 10/24/2024 | $35.00 | Buy | UBS |
| 10/11/2024 | $41.00 | Buy | Jefferies |
Morgan Stanley upgraded Nurix Therapeutics from Equal-Weight to Overweight and set a new price target of $36.00
Truist resumed coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $30.00
Mizuho initiated coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $24.00
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche's oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis) Bexobrutideg utilises a novel approach to eliminate the Bruton's Tyrosine Kinase (BTK) protein, potentially overcoming existing resistance mechanisms found with current standard-of-care BTK inhibitors Basel, 08 June 2026 - Roche ((SIX: RO, ROP, OTCQX:RHHBY) announced today that it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, Inc. (NASDAQ:NRIX). Under the terms of
Strategic collaboration combines Nurix's leadership in targeted protein degradation with Roche's portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clinical development plan in malignant hematology builds on the ongoing pivotal program in chronic lymphocytic leukemia (CLL) and includes therapeutic combination regimens across B cell malignancies Clinical development plan also includes expansion into neurology and immunology with plans for Phase 2 trials in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU) Nurix to receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milesto
In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib In healthy volunteers, both single- and multiple-ascending-dose oral dosing of bexobrutideg led to rapid and robust BTK degradation in blood and skin Phase 1 studies support continued exploration of new tablet formulation in inflammation and immunology indications BRISBANE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)
8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
SCHEDULE 13G - Nurix Therapeutics, Inc. (0001549595) (Subject)
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche's oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis) Bexobrutideg utilises a novel approach to eliminate the Bruton's Tyrosine Kinase (BTK) protein, potentially overcoming existing resistance mechanisms found with current standard-of-care BTK inhibitors Basel, 08 June 2026 - Roche ((SIX: RO, ROP, OTCQX:RHHBY) announced today that it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, Inc. (NASDAQ:NRIX). Under the terms of
SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology and as Chief Medical Officer and interim Chief Executive Officer of Seagen Inc., has had a distinguished career in hematology and oncology and over two decades of leadership experience in drug development and commercialization. "Roger
NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M license extension fee from ongoing collaboration with SanofiEnhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief commercial officerWell capitalized with cash and marketable securities of $549.7 million SAN FRANCISCO, April 08, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medi
Strategic collaboration combines Nurix's leadership in targeted protein degradation with Roche's portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clinical development plan in malignant hematology builds on the ongoing pivotal program in chronic lymphocytic leukemia (CLL) and includes therapeutic combination regimens across B cell malignancies Clinical development plan also includes expansion into neurology and immunology with plans for Phase 2 trials in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU) Nurix to receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milesto
600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential Accelerated Approval New preclinical data support bexobrutideg as potential best-in-class BTK degrader profile Nurix will host an investor webcast today, Wednesday, October 22nd, at 8:00 a.m. EDT SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced t
Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses Data reinforces Nurix's scientific leadership and platform strength in targeted protein degradation Nurix remains on track to initiate pivotal trials of bexobrutideg in 2025 Data are being presented at the 30th European Hematology Association Congress (EHA2025) Company will host a webcast conference call today, June 12, 2025, at 8:00 a.m. ET (2:00 p.m. CEST) SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clin
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)